Page of

Drug Shortages, Pricing, and Regulatory Activity

Drug Shortages, Pricing, and Regulatory Activity

Chapter:
(p.323) 10 Drug Shortages, Pricing, and Regulatory Activity
Source:
Measuring and Modeling Health Care Costs
Author(s):
Christopher Stomberg
Publisher:
University of Chicago Press
DOI:10.7208/chicago/9780226530994.003.0011

This study examines the patterns and causes of shortages in generic non-injectable drugs (e.g., tablets and topicals) in the United States. While shortages for injectable drugs have garnered more attention, shortages of other forms of prescription drugs have also been on the increase. In fact, they follow a strikingly similar trend with a number of important tablet drugs having recently been affected by shortage. This poses important questions about the root causes of these trends since most explanations found in the literature are specific to generic injectable drugs. Using a simple heuristic framework, three contributing factors are explored: regulatory oversight, potential market failures in pricing/reimbursement, and competition. This paper features an empirical examination of the contribution of changes in regulatory oversight to drug shortages. A pooled dynamic regression model using FDA data on inspections and citations reveals a statistically significant relationship between FDA regulatory activity (inspections and citations) and drug shortage rates. This result cuts across both injectable and non-injectable drugs, and could reveal a transition in equilibrium quality that should be transitory in nature, but it should also be interpreted with care given the other factors likely affecting shortage rates.

Keywords:   non-injectables, FDA, drug shortage, regulation

Sign In

Copyright © 2021. All rights reserved.
Privacy Policy and Legal Notice